KO 3 1 ATTACHMENT #3
NOV 2 0 2003
SECTION 9
510(k) SUMMARY
This 510(k) summary of safety and effectiveness for the ARAMIS II Dermatological Laser is
submitted in accordance with the requirements of SMDA 1990 and follows Office of Device
Evaluation guidance concerning the organization and content of a 510(k) summary.
Applicant: Quantel Medical
Address: QUANTEL MEDICAL
21 rue Newton
ZI du BREZET
63039 Clermont-Ferrand
Cedex 2
FRANCE
+33 (0)473 745 745
+33 (0)473 745 700 (Fax)
Contact Person: Mr. Jean Abascal :
(+33) 169 29 17 25
(+33) 169 29 17 29
Preparation Date: July 2003
(of the Summary)
Device Name: ARAMIS II Dermatological Laser
Common Name: — Er:Glass Laser
Classification Laser surgical instrument for use in general and plastic surgery and in
Name: dermatology (see: 21 CFR 878.4810).
Product Code: GEX
Panel: 79
Predicate devices: The Smoothbeam Laser System - K014128
Device description: The ARAMIS II Dermatological Laser emits a beam of coherent light at
1540 nms which is delivered to the hand pieces, including a cooling hand
piece, through a fiber optic.
Indications: The ARAMIS II Dermatological Laser system, in addition to previously
cleared indications, is intended for the treatment of back acne.

KOZ22U0 Dar

Performance Data: None required; the ARAMIS II claims substantial equivalence to the Candela
Smoothbeam based on comparisons of specifications/characteristics and
indications for use

CONCLUSION: Based on the information in this notification Quantel Medical concludes that
the ARAMIS II, indicated for the treatment of back acne, is substantially
equivalent to the Candela Smoothbeam.

rev. August 15, 2003

aie
e DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
LC
* Food and Drug Administration
9200 Corporate Boulevard
NOV 20 2003 Rockville MD 20850

Quantel Medical
c/o Mr. Roger W. Barnes
342 Sunset Bay Road
Hot Springs, Arkansas 71913
Re: K032260

Trade/Device Name: Aramis IT Dermatological Laser — New Indication

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and

plastic surgery and in dermatology

Regulatory Class: II

Product Code: GEX

Dated: October 22, 2003

Received: October 28, 2003
Dear Mr. Barnes:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medica! Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug.
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration. listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and
adulteration.
If your device is classified (see above) into either class II (Special Controls) or class II] (PMA). it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements. including. but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801): good manufacturing practice requirements us set
forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable. the electronic
product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.

Page 2 - Mr. Roger W. Barnes
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801). please
contact the Office of Compliance at (301) 594-4659. Also, please note the regulation ented.
"Misbranding by reference to premarket notification” (21CFR Part 807.97). You may obtain
other general information on your responsibilities under the Act from the Division of Small
Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or
(301) 443-6597 or at its Internet address http://www.fda.gov/cedrh/dsma/dsmamain.htm!|

Sincerely yours,

(or--Celia M. Witten, Ph.D.. M.D.
Director
Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and Radiological Health
Enclosure

SECTION 7

INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K 0 2 226 0

Device Name: Aramis II Dermatological Laser - New indication

Indications for Use Statement:

The Aramis II Dermatological Laser system is intended for the treatment of back acne.
(Division Sign-Off) .
Division of General, Restorative
and Neurological Devices
642260
510(k) Number
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
re of CDRH, Office of Device Evaluation
Prescription Use _v_ OR Over-The Counter Use __
. (Per 21 CFR 801.109)
020

